Xenon Pharmaceuticals (XENE) Long-Term Investments (2022 - 2026)

Xenon Pharmaceuticals (XENE) has 5 years of Long-Term Investments data on file, last reported at $244.9 million in Q1 2026.

• Long-Term Investments for Q1 2026 came in at $244.9 million, up 73.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $244.9 million (up 73.06% YoY), and the FY2025 annual result was $37.2 million, down 70.86% from the prior year.
• Long-Term Investments advanced to $244.9 million in Q1 2026 per XENE's latest filing, from $37.2 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $292.8 million in Q4 2023 and troughed at $37.2 million in Q4 2025.
• A 5-year average of $144.4 million and a median of $129.1 million in 2024 frame the typical range for Long-Term Investments.
• The sharpest annual moves came in 2023 and 2025: Long-Term Investments surged 127.53% in 2023, then plunged 70.86% in 2025.
• A 5-year view of Long-Term Investments shows it stood at $128.7 million in 2022, then surged by 127.53% to $292.8 million in 2023, then plunged by 56.46% to $127.5 million in 2024, then sank by 70.86% to $37.2 million in 2025, then jumped by 559.11% to $244.9 million in 2026.
• Business Quant data shows XENE's Long-Term Investments at $244.9 million in Q1 2026, $37.2 million in Q4 2025, and $93.0 million in Q3 2025.